AstraZeneca Reports Positive Survival In Phase 3 Trial Of ENHERTU In HER2 Metastatic Breast Cancer

LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) Wednesday announced that ENHERTU, a HER2-directed antibody-drug conjugate or ADC, achieved statistically significant overall survival, reducing the risk

Related Keywords

San Antonio ,Texas ,United States ,London ,City Of ,United Kingdom ,Trastuzumab Emtansine ,Daiichi Sankyo ,Astrazeneca ,Antonio Breast Cancer ,Reports ,Positive ,Survival ,Hase ,Trial ,Enhertu ,Ther2 ,Metastatic ,Breast ,Dancer ,